Mayne Pharma Group (AU:MYX) has released an update.
Mayne Pharma Group reported a significant 112% increase in revenue for the year ending June 2024, but also a net loss after tax, contrasting with the previous year’s profit. The report indicates a challenging year with substantial losses from continuing operations and the incorporation of a new entity, Mayne Pharma Distribution Services LLC. Shareholders faced a diluted earnings per share of ($2.19) and no final dividend, reflecting the company’s performance and strategic adjustments.
For further insights into AU:MYX stock, check out TipRanks’ Stock Analysis page.
